Lean oncology: a new model for oncologists

Por Montesarchio, Vincenzo, Grimaldi, Antonio Maria, Fox, Bernard A, Rea, Antonio, Marincola, Francesco M, Ascierto, Paolo A
Publicado em 2012

Do BRAF inhibitors select for populations with different disease progression kinetics?

Por Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Publicado em 2013

Serious haematological toxicity during and after ipilimumab treatment: a case series

Por Simeone, Ester, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Palla, Marco, Paone, Miriam, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado em 2014

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Por Stucci, Stefania, Tucci, Marco, Ascierto, Paolo Antonio, Passarelli, Anna, Mariaelena, Capone, Madonna, Gabriele, Ester, Simeone, Grimaldi, Antonio Maria, Silvestris, Franco
Publicado no J Transl Med (2015)

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series

Por Di Monta, Gianluca, Caracò, Corrado, Marone, Ugo, Grimaldi, Antonio Maria, Anniciello, Anna Maria, Di Marzo, Massimiliano, Simeone, Ester, Mori, Stefano
Publicado no BMC Res Notes (2015)

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

Por Montella, Maurizio, Gandini, Sara, Rossi, Carlo Riccardo, Testori, Alessandro, Mastrangelo, Giuseppe, Serraino, Diego, Budroni, Mario, Crispo, Anna, Grimaldi, Antonio Maria, Ascierto, Paolo Antonio
Publicado em 2014

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report

Por Falivene, Sara, Giugliano, Francesca Maria, Grimaldi, Antonio Maria, Di Franco, Rossella, Toledo, Diego, Muto, Matteo, Cammarota, Fabrizio, Borzillo, Valentina, Ascierto, Paolo Antonio, Muto, Paolo
Publicado em 2014

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Por Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Vanella, Vito, Palla, Marco, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado no Oncoimmunology (2017)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

Por Grimaldi, Antonio Maria, Simeone, Ester, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Publicado no J Immunother Cancer (2015)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

Por Simeone, Ester, Benedetto, Lucia, Gentilcore, Giusy, Capone, Marilena, Caracò, Corrado, Di Monta, Gianluca, Marone, Ugo, Di Cecilia, Marialuisa, Grimaldi, Antonio Maria, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo A
Publicado em 2014

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

Por Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Rinaldi, Giovanni, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Publicado no J Immunother Cancer (2015)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

Por Daponte, Antonio, Signoriello, Simona, Maiorino, Luigi, Massidda, Bruno, Simeone, Ester, Grimaldi, Antonio Maria, Caracò, Corrado, Palmieri, Giuseppe, Cossu, Antonio, Botti, Gerardo, Petrillo, Antonella, Lastoria, Secondo, Cavalcanti, Ernesta, Aprea, Pasquale, Mozzillo, Nicola, Gallo, Ciro, Comella, Giuseppe, Ascierto, Paolo Antonio
Publicado em 2013

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

Por Simeone, Ester, Romano, Maria fiammetta, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Paone, Miriam, Rinaldi, Giovanni, Di monta, Gianluca, Di marzo, Massimiliano, Hauber, Federica, Festino, Lucia, D'Angelillo, Anna, Romano, Simona, Staibano, Stefania, Ilardi, Gennaro, Bisogni, Rita, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado no J Immunother Cancer (2014)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Por Chiarion Sileni, Vanna, Pigozzo, Jacopo, Ascierto, Paolo Antonio, Grimaldi, Antonio Maria, Maio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, de Rosa, Francesco, Nuzzo, Carmen, Testori, Alessandro, Cocorocchio, Emilia, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Merelli, Barbara, Parmiani, Giorgio, Rinaldi, Gaetana, Aglietta, Massimo, Grosso, Marco, Queirolo, Paola
Publicado em 2014